Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

Li, Si Ni; Wan, Xiaomin; Peng, Liu Bao; Li, Ya Min; Li, Jian He

doi:10.1186/s12913-023-09058-7

Table 1 Input parameters of model

From: Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

Parameters	Mean	Range	distribution	Reference
Survival model of PFS in the full cohort
Atezolizumab + vemurafenib + cobimetinib	Shape = 1.375; Scale = 13.807		Loglogistic	[9]
Vemurafenib + cobimetinib	Shape = 1.663; Scale = 10.926		Loglogistic	[9]
Dabrafenib + trametinib	Shape = 1.4075; Scale = 12.9753		Loglogistic	[11]
Encorafenib + binimetinib	Shape = 1.668; Scale = 14.080		Loglogistic	[10]
Nivolumab	Shape = 1.2021; Scale = 4.6024		Loglogistic	[17]
OS in the best support care	Shape = 1.757; Scale = 7.007		Loglogistic	[21]
Probability of treatment discontinuation as a result of AE (%)
Atezolizumab + vemurafenib + cobimetinib	13		Beta	[9]
Vemurafenib + cobimetinib	16		Beta	[9]
Dabrafenib + trametinib	26		Beta	[11]
Encorafenib + Binimetinib	13		Beta	[10]
Nivolumab	3		Beta	[17]
Probability of treatment mortality as a result of AE (%)
Atezolizumab + vemurafenib + cobimetinib	NA		Beta	[9]
Vemurafenib + cobimetinib	NA		Beta	[9]
Dabrafenib + trametinib	1.5		Beta	[11]
Encorafenib + Binimetinib	0		Beta	[10]
Nivolumab	0		Beta	[17]
Probability of background death	–	–	–	[16]
Drug cost, $ (per mg)
Atezolizumab	7.82	6.26–9.38	Gamma	[22]
Vemurafenib	0.16	0.13–0.19	Gamma	[23,24,25]
Cobimetinib	4.32	3.46–5.18	Gamma	[23,24,25]
Dabrafenib	0.89	0.71–1.07	Gamma	[23,24,25]
Trametinib	144.95	115.96–173.94	Gamma	[23,24,25]
Encorafenib	0.89	0.71–1.07	Gamma	[24,25,26]
Binimetinib	4.63	3.70–5.56	Gamma	[24, 25, 27]
Nivolumab	28.54	22.83–32.25	Gamma	[22]
Cost of best support care	4319	3455.2–5182.8	Gamma	[28]
Management of AEs, $
Atezolizumab + vemurafenib + cobimetinib	972	687.6–1166.4	Gamma	[29]
Vemurafenib + cobimetinib	1080	864–1296	Gamma	[29]
Dabrafenib + trametinib	1229	921-1536^a	Gamma	[28]
Encorafenib + Binimetinib	1587	1269.6–1904.4	Gamma	[29]
Nivolumab	2688	2150.4–3225.6	Gamma	[25]
Administration cost
IV infusion, single or initial drug (≤1 hour)	148.3	118.64–177.93	Gamma	[30]
Utilities
Complete/partial response	0.88	0.70–1.00	Beta	[4]
Stable disease	0.80	0.64–0.96	Beta	[4]
Progressive disease	0.52	0.42–0.62	Beta	[4]
Disutility due to AEs (grade ≥ 3)	0.077	0.074–0.08^a	Beta	[28]
Average patient weight (kg)	70		Normal	[4]
Terminal care, $	17,346	13,009 – 21682^a	Gamma	[28]

^aThe range is the reported or estimated 95% CI

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Health Services Research

Contact us